PharmaCielo Ltd.
PCLOF
$0.03
-$0.01-17.21%
OTC PK
| 06/30/2025 | 09/30/2024 | 06/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 233.10K | 974.30K | 572.70K | 572.70K | 178.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 233.10K | 974.30K | 572.70K | 572.70K | 178.20K |
| Cost of Revenue | 277.00K | 701.80K | 371.90K | 371.90K | 473.80K |
| Gross Profit | -43.90K | 272.60K | 200.80K | 200.80K | -295.60K |
| SG&A Expenses | 600.90K | 903.80K | 1.39M | 1.39M | 925.80K |
| Depreciation & Amortization | 14.50K | 34.90K | 37.00K | 37.00K | 69.50K |
| Other Operating Expenses | -128.60K | -26.50K | -16.00K | -16.00K | -1.80K |
| Total Operating Expenses | 763.80K | 1.61M | 1.79M | 1.79M | 1.47M |
| Operating Income | -530.70K | -639.60K | -1.21M | -1.21M | -1.29M |
| Income Before Tax | -940.30K | -1.94M | -1.88M | -1.88M | -1.80M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -940.30K | -1.94M | -1.88M | -1.88M | -1.80M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -940.30K | -1.94M | -1.88M | -1.88M | -1.80M |
| EBIT | -530.70K | -639.60K | -1.21M | -1.21M | -1.29M |
| EBITDA | -516.20K | -611.20K | -1.18M | -961.90K | -1.22M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 187.98M | 162.03M | 169.75M | 169.75M | 169.30M |
| Average Diluted Shares Outstanding | 187.98M | 162.03M | 169.75M | 169.75M | 169.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |